Navigation Links
Potential new treatment may protect celiac patients from gluten-induced injury
Date:6/12/2014

Bethesda, MD (June 12, 2014) The gluten-specific enzyme ALV003 reduces a patient's exposure to gluten and its potential harm, according to a new phase 2 study appearing in Gastroenterology1, the official journal of the American Gastroenterological Association. This study is the first to find that a non-dietary intervention can potentially benefit celiac disease patients.

Study participants were put on an everyday gluten-free diet, challenged with up to 2 grams of gluten daily (equivalent to approximately one half of a standard slice of bread in the U.S.). Researchers found that daily oral administration of ALV003, at the time of gluten ingestion, decreased gluten-induced injury to the small intestine. The treatment appeared to be well tolerated. Gastrointestinal symptoms, such as nausea and abdominal pain, were greater in the placebo group compared with those receiving active treatment.

"Total avoidance of gluten is, at best, challenging," said lead study author, Marja-Leena Lahdeaho, University of Tampere, Tampere University Hospital, Finland. "The potential of ALV003 for celiac disease is significant given that ongoing exposure to low levels of gluten can cause patients to experience persistent symptoms and chronic intestinal inflammation, despite following a strict gluten-free diet."

Gluten is widely used in the food and other industries. Cross contamination during food processing is difficult to avoid and the labeling of food products can be inaccurate, misleading or incorrect. The gluten-free diet is socially troublesome, expensive and compliance is problematic. Additionally, traces of gluten can be found in common items such as envelope glue and makeup. These challenges lead to consumption of small amounts of gluten in even the most cautious patients. Thus, there is a need for the development of a pharmacologic therapy that will work with or replace a gluten-free diet.

As the first evidence of a therapeutic intervention for celiac disease meeting primary endpoints, this randomized, double-blind, placebo-controlled clinical trial is a welcomed addition to celiac research. Future studies are warranted before ALV003 can come to market; a 500-person multi-center trial is currently ongoing.


'/>"/>

Contact: Rachel Steigerwald
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Related biology news :

1. Epigenetic signatures direct the repair potential of reprogrammed cells
2. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
3. Interventional radiology: Potential breakthrough to treat mens enlarged prostate
4. Researchers report potential for a moderate New England red tide in 2012
5. Gallbladder shown as potential stem cell source for regenerative liver and metabolic disease
6. Researchers find potential dark side to diets high in beta-carotene
7. Beehive extract shows potential as prostate cancer treatment
8. Gene therapy for hearing loss: Potential and limitations
9. Folic acid food enrichment potentially protective against childhood cancers
10. Nuisance seaweed found to produce compounds with biomedical potential
11. Potential new approach to regenerating skeletal muscle tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  In vitro diagnostic (IVD) ... mergers and acquisitions (M&A), and Kalorama Information expects that ... acquisitions have been shifting. Generally, uncertainty in reimbursement and ... the U.S. has changed the acquisitions landscape. Instead of ... in companies buying partners outside of their home country ...
(Date:1/12/2017)... NEW YORK , Jan. 12, 2017  New research ... around the office of the future.  1,000 participants were simply ... last three months which we may consider standard issue.  Insights ... office of 2017 were also gathered from futurists and industry ... and Dr. James Canton .  Some ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, Inc., ... in healthy volunteers of a novel calcium release-activated ... acute pancreatitis. Acute pancreatitis, sudden ... mild disorder, but can be very serious.  In severe ... sepsis, where extended hospital stays, time in the ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... 2017   Boston Biomedical , an industry leader ... cancer stemness pathways, will feature data from two clinical ... 2017 ASCO Gastrointestinal Cancers Symposium, held from January 19-21, ... Napabucasin is an orally-administered investigational agent designed to ... Cancer stem cells (CSCs) possess the property of stemness ...
(Date:1/18/2017)...   Parent Project Muscular Dystrophy (PPMD) , a ... muscular dystrophy (Duchenne) , today announced a $600,000 grant ... Technology (NJIT) and Talem Technologies (Talem) as part of ... to assist people living with Duchenne. PPMD is funding ... embedded computer, software, a force sensor and a motor ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on Wednesday, ... Stream, NY. The procedure was an anterior cervical discectomy and fusion on a ...
(Date:1/18/2017)... Frederick, Maryland (PRWEB) , ... January 18, 2017 ... ... of two new federally funded bio-focused Manufacturing Innovation Institutes (MII). U.S. Secretary of ... Innovation in Manufacturing Biopharmaceuticals (NIIMBL), and the Department of Defense has announced the ...
Breaking Biology Technology: